Carl Hansen
Co-Founder, President & CEO
AbCellera
2026-02-27
If it plays out as we hope, though there is still risk, we’ll have what I think is a clear shot to a potential blockbuster therapy for women who choose not to use hormone therapy, or cannot use it due to contraindications, with a more convenient dosing, a better safety profile, and potentially better efficacy.